Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Immunotherapy Propels Urothelial Carcinoma Treatment Advances
February 2nd 2023Stephanie A. Berg, DO, highlights ongoing urothelial cancer clinical trials; the role of single-agent immunotherapy and combinations in this disease; and the importance of future research that prioritizes and guides individualized patient care.
Mutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC
February 1st 2023Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations, and emphasized the need for further research in this area to determine which patients are most likely to benefit from certain therapies based on their molecular profiles.
Three-Drug Combination Therapy Effective in Patients with High-Risk CLL, Trial Shows
February 1st 2023A three-drug combination that sent chronic lymphocytic leukemia into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.
Further Study and Tailored Treatments Remain Unmet Needs in Male Breast Cancer
January 30th 2023Jose Pablo Leone, MD, discusses the distinguishing features of male breast cancer, explains the benefits and limitations of current treatments, and emphasizes the importance of raising awareness about this breast cancer subset to propel further research.
Novel Combinations Promote Individualized Care in Bladder and Prostate Cancer
January 24th 2023Alicia Morgans, MD, MPH, discussed the evolving role of androgen deprivation therapy in metastatic hormone-sensitive prostate cancer, investigational immunotherapy combinations in urothelial cancer, and how antibody-drug conjugates provide a unique means of delivering toxic agents directly to tumors.
CAR-T-cell Shows Promise in Patients With Lymphoma of the Brain and Spinal Cord in Early Trial
January 24th 2023A CAR-T-cell therapy known as axicabtagene ciloleucel is safe and shows encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord.
Paper Proposes New Community-Oriented Fellowship Training Model for Hematologists/Oncologists
December 22nd 2022As patients with cancer increasingly receive treatment in community hospitals and clinics and many such centers experience a shortage of oncologists, a group of physicians at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School has proposed the first-ever training blueprint for oncologists planning careers in a community or academic-community setting.
Scientists Map Genetic Evolution of Chronic Lymphocytic Leukemia to Richter Syndrome
December 21st 2022In a new study, scientists reveal for the first time the genomic differences between chronic lymphocytic leukemia and Richter's, the molecular pathways by which Richter's emerges, and the existence of multiple subtypes of the disease.
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
Treatment with zanubrutinib (Brukinsa) reduced the risk of progression or death by 35% compared with ibrutinib (Imbruvica) for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
December 5th 2022Dr Matulonis discusses the FDA approval of mirvetuximab soravtansine-gynx in folate receptor alpha–positive, platinum-resistant ovarian cancer, key efficacy and safety data from the SORAYA trial, and how further research can continue the momentum behind finding effective ovarian cancer treatments.